Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cangrelor platelet inhibition in comatose survivors of out-of-hospital cardiac arrest undergoing primary PCI
2019-001285-15Phase 4Completed
- Sponsor
- University Medical Centre Ljubljana
- Start
- Mar 2019
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of cangrelor in myocardial infarction (MI) and cardiac morbidity, sponsored by University Medical Centre Ljubljana. Primary endpoint: Platelet inhibition measured by VerifyNow and Multiplate. Started Mar 2019; status: completed.
02
Drugs
cangrelor
03
Conditions
myocardial infarction (MI)cardiac morbidity
Beyond the preview
Go deeper on 2019-001285-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001285-15.